MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

This trial is testing a new injected drug called MDN-001 for people with primary liver cancer (hepatocellular carcinoma) that cannot be surgically removed or ablated. This is an early-phase study examining how safe the drug is and whether it shows signs of shrinking tumors. **You may be eligible if...** - You are 18 to 80 years old - You have been clinically or pathologically diagnosed with primary liver cancer (hepatocellular carcinoma) - Your liver function is reasonably preserved (Child-Pugh A or mild B) - Your cancer cannot be removed by surgery or ablation, or you prefer not to have those procedures - You have at least one measurable liver tumor that is at least 1cm - Your general health is good (ECOG score 0–1) and expected survival is at least 3 months **You may NOT be eligible if...** - You have already received certain prior cancer treatments that conflict with this trial - Your liver function is severely impaired - You have serious heart, kidney, or blood problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.